Clinical study of Lamivudine treatment in patients with decompensated cirrhosis

Lamivudine is a nucleoside analogue and is highly effective in suppressing hepatitis B viral replication.The potential for recovery of hepatic decompensation in patients with posthepatitic cirrhosis treated with lamivudine has seldom been reported.9 patients with decompensated cirrhosis were treated with lamivudine 100mg once daily for at least 6 months and their HBsAg and HBV DNA were all positive.6 of 9 patients had Child-Pugh class B and 3 of 9 patients had Child-Pugh class C liver disease.All patients remained a stable liver funcion and their HBV-DNA converted to negative,their child-Pugh score decreased≥2 except 1 patient died.Lamivudine can improve the liver function and reduce Child-pugh score of decompensated cirrhosis by inhibiting the replication of HBV DNA.